{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:04:11Z","timestamp":1784811851483,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Bone marrow carcinomatosis (BMC) is a rare but clinically relevant manifestation of metastatic breast cancer (mBC), characterized by diffuse marrow infiltration and hematologic dysfunction. Evidence on epidemiology, clinical presentation, prognosis, and optimal treatment is limited. We performed a bicentric retrospective real-world analysis of patients diagnosed with BMC, representing the largest reported European cohort to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 37 patients diagnosed with BMC at two German university breast cancer centers between 2010 and 2023. Clinical characteristics, hematologic abnormalities, metastatic patterns, treatments, and overall survival (OS) were evaluated. Incidence estimates were calculated based on institutional breast cancer and mBC populations. A systematic literature review contextualized the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The estimated incidence of BMC was 2.6% among patients with mBC and 0.5% among all breast cancer cases. Most patients had HR-positive\/HER2-negative disease (89%). Hematologic abnormalities were frequent, including anemia (84%), thrombocytopenia (76%), and pancytopenia (57%). Median OS after BMC diagnosis was 12 months (95% CI 6.0\u201338.0). Patients with bone-only metastases did not reach median OS, whereas those with additional metastatic sites had a median OS of 9 months (95% CI 5.0\u201312.0). Patients receiving endocrine therapy plus CDK4\/6 inhibition showed numerically longer OS (34 months, 95% CI 5.0\u2013NA) compared with chemotherapy alone (12 months, 95% CI 5.0\u201338.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BMC remains a rare but challenging complication of mBC. Endocrine-based targeted therapy may improve outcomes in selected HR-positive\/HER2-negative patients. Larger multicenter studies are needed to optimize diagnosis and treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06546-1","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:56:00Z","timestamp":1784775360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers"],"prefix":"10.1007","volume":"152","author":[{"given":"Nikolas","family":"Tauber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Neubacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"P. Cieslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Fick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Freier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Friebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Hemptenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"Hilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Muras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E. M.","family":"Polkaehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Princk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Ruckh\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Rody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Kohls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"6546_CR1","doi-asserted-by":"publisher","first-page":"e2300285","DOI":"10.1200\/GO.23.00285","volume":"10","author":"S Al Sukhun","year":"2024","unstructured":"Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NDM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, Saghir E, Arun NS BK (2024) Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource\u2013Stratified Guideline. JCO Global Oncol 10:e2300285. https:\/\/doi.org\/10.1200\/GO.23.00285","journal-title":"JCO Global Oncol"},{"issue":"2","key":"6546_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/1078155213480201","volume":"20","author":"M Artac","year":"2014","unstructured":"Artac M, Koral L, Toy H, Guler T, Boruban MC, Altundag K (2014) Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases. J Oncol Pharm Pract 20(2):141\u2013145. https:\/\/doi.org\/10.1177\/1078155213480201","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"6546_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","volume":"34","author":"L Castelo-Branco","year":"2023","unstructured":"Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Koopman M (2023) ESMO Guidance for Reporting Oncology real-World evidence (GROW). Ann Oncol 34(12):1097\u20131112. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.001","journal-title":"Ann Oncol"},{"issue":"15","key":"6546_CR4","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1158\/1078-0432.Ccr-04-2420","volume":"11","author":"M Chavez-Macgregor","year":"2005","unstructured":"Chavez-Macgregor M, Aviles-Salas A, Green D, Fuentes-Alburo A, G\u00f3mez-Ruiz C, Aguayo A (2005) Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res 11(15):5396\u20135400. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-2420","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6546_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/tbj.12264","volume":"20","author":"L Demir","year":"2014","unstructured":"Demir L, Akyol M, Bener S, Payzin KB, Erten C, Somali I, Can A, Dirican A, Bayoglu V, Kucukzeybek Y, Alacacioglu A, Calli AO, Tarhan MO (2014) Prognostic evaluation of breast cancer patients with evident bone marrow metastasis. Breast J 20(3):279\u2013287. https:\/\/doi.org\/10.1111\/tbj.12264","journal-title":"Breast J"},{"issue":"5","key":"6546_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00404-025-08120-5","volume":"312","author":"M Fern\u00e1ndez-Pacheco","year":"2025","unstructured":"Fern\u00e1ndez-Pacheco M, Gerken M, Ignatov A, Seitz S, Kowalski C, Sturm-Inwald EC, Hatzipanagiotou ME, Ortmann O (2025) Chemotherapy in elderly patients with early breast cancer: a systematic review. Arch Gynecol Obstet 312(5):1387\u20131418. https:\/\/doi.org\/10.1007\/s00404-025-08120-5","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"6546_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00404-025-08031-5","volume":"312","author":"F Ganster","year":"2025","unstructured":"Ganster F, Schrodi S, Braun M, Seifert C, Mahner S, Kolben T, Wuerstlein R, Harbeck N, Burgmann M (2025) Breast cancer in patients under 40 years: an 11-year retrospective cohort analysis. Arch Gynecol Obstet 312(2):583\u2013593. https:\/\/doi.org\/10.1007\/s00404-025-08031-5","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"6546_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Harbeck N (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"issue":"8","key":"6546_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tr\u00e9dan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O\u2019Shaughnessy J, Pivot X, Tolaney SM, Hurvitz SA, Llombart-Cussac A, Andr\u00e9 V, Saha A, van Hal G, Johnston SRD (2024) Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 35(8):718\u2013727. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.013","journal-title":"Ann Oncol"},{"key":"6546_CR10","doi-asserted-by":"publisher","first-page":"S459","DOI":"10.1016\/j.annonc.2025.08.1032","volume":"36","author":"Y Haborets","year":"2025","unstructured":"Haborets Y, Shevnia S (2025) 610P Systemic therapy for bone marrow carcinomatosis in metastatic breast cancer: Is there a chance when there seems to be none? Ann Oncol 36:S459. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1032","journal-title":"Ann Oncol"},{"key":"6546_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/wjs.70147","author":"GJ Hill","year":"2025","unstructured":"Hill GJ, Hegarty A, Dowling GP, Hembrecht S, Daly GR, Roche T, Downey E, Allen M, Power C, Healy N, Young LS, Hill ADK (2025) Survival Outcomes in Breast Cancer Patients With Metastatic Bone Disease. World J Surg. https:\/\/doi.org\/10.1002\/wjs.70147","journal-title":"World J Surg"},{"issue":"10","key":"6546_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"N Hortobagyi Gabriel","year":"2022","unstructured":"Hortobagyi Gabriel N, Salomon S, Burris Howard M, Yap A, Gabe Y-SS, Hart S, Campone L, Petrakova M, Eric KW, Janni P, Conte W, Cameron David P, Andr\u00e9 A, Arteaga Carlos F, Juan LZ, Chakravartty P, Taran A, Le Gac T, Serra F, P., O\u2019Shaughnessy J (2022) Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 386(10):942\u2013950. https:\/\/doi.org\/10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"key":"6546_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"6546_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41523-021-00289-7","volume":"7","author":"S Johnston","year":"2021","unstructured":"Johnston S, O\u2019Shaughnessy J, Martin M, Huober J, Toi M, Sohn J, Andr\u00e9 VAM, Martin HR, Hardebeck MC, Goetz MP (2021) Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer 7(1):80. https:\/\/doi.org\/10.1038\/s41523-021-00289-7","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"6546_CR15","first-page":"4025","volume":"31","author":"HG Kopp","year":"2011","unstructured":"Kopp HG, Krauss K, Fehm T, Staebler A, Zahm J, Vogel W, Kanz L, Mayer F (2011) Symptomatic bone marrow involvement in breast cancer\u2013clinical presentation, treatment, and prognosis: a single institution review of 22 cases. Anticancer Res 31(11):4025\u20134030","journal-title":"Anticancer Res"},{"issue":"7","key":"6546_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2018.03.009","volume":"44","author":"M Lagendijk","year":"2018","unstructured":"Lagendijk M, van Egdom LSE, Richel C, van Leeuwen N, Verhoef C, Lingsma HF, Koppert LB (2018) Patient reported outcome measures in breast cancer patients. Eur J Surg Oncol 44(7):963\u2013968. https:\/\/doi.org\/10.1016\/j.ejso.2018.03.009","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"6546_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.Ccr-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Vazquez V, Jung R, Babu KH, Wheatley-Price KG, De Laurentiis P, Im M, Kuemmel YH, Tripathy S, D (2022) Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+\/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res 28(5):851\u2013859. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3032","journal-title":"Clin Cancer Res"},{"issue":"23","key":"6546_CR18","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/jco.24.00144","volume":"42","author":"YS Lu","year":"2024","unstructured":"Lu YS, Mahidin E, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, El Saghir NS (2024) Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol 42(23):2812\u20132821. https:\/\/doi.org\/10.1200\/jco.24.00144","journal-title":"J Clin Oncol"},{"key":"6546_CR19","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3389\/fonc.2020.00864","volume":"10","author":"S Nardin","year":"2020","unstructured":"Nardin S, Mora E, Varughese FM, D\u2019Avanzo F, Vachanaram AR, Rossi V, Saggia C, Rubinelli S, Gennari A (2020) Breast Cancer Survivorship, Quality of Life, and Late Toxicities. Front Oncol 10:864. https:\/\/doi.org\/10.3389\/fonc.2020.00864","journal-title":"Front Oncol"},{"key":"6546_CR20","unstructured":"National Cancer Insitute (2025) Female Breast Cancer- Cancer Stat and Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"issue":"9","key":"6546_CR21","doi-asserted-by":"publisher","first-page":"10672","DOI":"10.1002\/cam4.5827","volume":"12","author":"L Niu","year":"2023","unstructured":"Niu L, Lv H, Zhang M, Zeng H, Fu S, Cui S, Liu Z, Yan M (2023) Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10-year, single-center, real-world study of 67 cases. Cancer Med 12(9):10672\u201310683. https:\/\/doi.org\/10.1002\/cam4.5827","journal-title":"Cancer Med"},{"key":"6546_CR22","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McKenzie JE (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"6546_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrc.2014.11.002","volume":"3","author":"G Pahouja","year":"2015","unstructured":"Pahouja G, Wesolowski R, Reinbolt R, Tozbikian G, Berger M, Mangini N, Lustberg MB (2015) Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. Cancer Treat Commun 3:28\u201332. https:\/\/doi.org\/10.1016\/j.ctrc.2014.11.002","journal-title":"Cancer Treat Commun"},{"issue":"1","key":"6546_CR24","doi-asserted-by":"publisher","first-page":"107308","DOI":"10.1016\/j.ejso.2023.107308","volume":"50","author":"C Ren","year":"2024","unstructured":"Ren C, Sun J, Kong L, Wang H (2024) Breast surgery for patients with de novo metastatic breast cancer: A meta-analysis of randomized controlled trials. Eur J Surg Oncol 50(1):107308. https:\/\/doi.org\/10.1016\/j.ejso.2023.107308","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"6546_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ (2019) Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174(3):719\u2013729. https:\/\/doi.org\/10.1007\/s10549-018-05125-4","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6546_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/tbj.13647","volume":"26","author":"A Sakin","year":"2020","unstructured":"Sakin A, Sakalar T, Sahin S, Yasar N, Demir C, Geredeli C, Cihan S (2020) Factors affecting survival and treatment efficacy in breast cancer patients with bone marrow metastasis. Breast J 26(4):815\u2013818. https:\/\/doi.org\/10.1111\/tbj.13647","journal-title":"Breast J"},{"issue":"39","key":"6546_CR27","first-page":"647","volume":"120","author":"J Schmitt","year":"2023","unstructured":"Schmitt J, Klinkhammer-Schalke M, Bierbaum V, Gerken M, Bobeth C, R\u00f6\u00dfler M, Dr\u00f6ge P, Ruhnke T, G\u00fcnster C, -van Kleihues K, Schoffer O (2023) Initial Cancer Treatment in Certified Versus Non-Certified Hospitals. Dtsch Arztebl Int 120(39):647\u2013654. https:\/\/www.aerzteblatt.de\/int\/article.asp?id=233578","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"6546_CR28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/jco.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS (2024) Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J Clin Oncol 42(9):994\u20131000. https:\/\/doi.org\/10.1200\/jco.23.00137","journal-title":"J Clin Oncol"},{"issue":"8042","key":"6546_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","volume":"636","author":"GS Sonke","year":"2024","unstructured":"Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, Guerrero Paez C, Mol L, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van Schaik C, Tol J, van Tromp- CS, Vrijaldenhoven S, Consortium SS (2024) Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature 636(8042):474\u2013480. https:\/\/doi.org\/10.1038\/s41586-024-08035-2","journal-title":"Nature"},{"issue":"11","key":"6546_CR30","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/s1470-2045(19)30616-3","volume":"20","author":"AR Tan","year":"2019","unstructured":"Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnovi\u0107 \u017d, Vasev N, Ma L, Richards DA, Wilks ST, Milenkovi\u0107 D, Yang Z, Antal JM, Morris SR, O\u2019Shaughnessy J (2019) Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol 20(11):1587\u20131601. https:\/\/doi.org\/10.1016\/s1470-2045(19)30616-3","journal-title":"Lancet Oncol"},{"key":"6546_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061121","author":"N Tauber","year":"2024","unstructured":"Tauber N, Cirkel C, Claussen A, Fick F, Kontomanolis E, Krawczyk N, Rody A, Banys-Paluchowski M (2024) HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation? Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16061121","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6546_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00404-025-08028-0","volume":"312","author":"N Tauber","year":"2025","unstructured":"Tauber N, Amann N, Dannehl D, Deutsch TM, Dimpfl M, Fasching P, Hartkopf A, Heublein S, Hilmer L, H\u00f6rner M, Krawczyk N, Kr\u00fcckel A, Krug D, Marm\u00e9 F, Michel LL, Reinisch M, Rody A, Sch\u00e4ffler H, Schneeweiss A, Banys-Paluchowski M (2025) Therapy of early breast cancer: current status and perspectives. Arch Gynecol Obstet 312(2):311\u2013328. https:\/\/doi.org\/10.1007\/s00404-025-08028-0","journal-title":"Arch Gynecol Obstet"},{"issue":"7","key":"6546_CR33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/s1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Vazquez V, Jung R, Babu KH, Wheatley-Price KG, De Laurentiis P, Im M, Kuemmel YH, El-Saghir S, Lu N, Y. S (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904\u2013915. https:\/\/doi.org\/10.1016\/s1470-2045(18)30292-4","journal-title":"Lancet Oncol"},{"key":"6546_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.111303","author":"P van Dam","year":"2025","unstructured":"van Dam P, Tomatis M, Ponti A, Marotti L, Verhaegen J, Aristei C, Cardoso MJ, Cheung KL, Curigliano G, De Vries J, Santini D, Sardanelli F, Rubio IT (2025) Locally advanced breast cancers: the EUSOMA experience. Eur J Surg Oncol. https:\/\/doi.org\/10.1016\/j.ejso.2025.111303","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"6546_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000505532","volume":"13","author":"T Yamaguchi","year":"2020","unstructured":"Yamaguchi T, Masumoto M, Sakurai U, Nakane M (2020) Disseminated Carcinomatosis of the Bone Marrow from Occult Breast Cancer Responding to a Sequence of Endocrine Therapy. Case Rep Oncol 13(1):193\u2013199. https:\/\/doi.org\/10.1159\/000505532","journal-title":"Case Rep Oncol"},{"key":"6546_CR36","doi-asserted-by":"publisher","first-page":"1042773","DOI":"10.3389\/fonc.2022.1042773","volume":"12","author":"R Yang","year":"2022","unstructured":"Yang R, Jia L, Lu G, Lv Z, Cui J (2022) Symptomatic bone marrow metastases in breast cancer: A retrospective cohort study. Front Oncol 12:1042773. https:\/\/doi.org\/10.3389\/fonc.2022.1042773","journal-title":"Front Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06546-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06546-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06546-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:45:00Z","timestamp":1784810700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06546-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6546"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06546-1","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Nikolas Tauber reports a relationship with Novartis that includes: board membership, consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Nikolas Tauber reports a relationship with Pfizer that includes: funding grants, speaking and lecture fees. Nikolas Tauber reports a relationship with Astra Zeneca that includes: travel reimbursement, consulting or advisory, speaking and lecture fees. Nikolas Tauber reports a relationship with ExactSciences that includes: speaking and lecture fees. Nikolas Tauber reports a relationship with Daiichi Sankyo that includes: non-financial support and travel reimbursement. Nikolas Tauber reports a relationship with Stemline that includes: travel reimbursement, speaking and lecture fees. Nikolas Tauber reports a relationship with Georg Thieme Verlag KG that includes: board membership and non-financial support. Nikolas Tauber reports a relationship with if-kongress that includes: speaking and lecture fees and travel reimbursement. Nikolas Tauber reports a relationship with Deltamed that includes: speaking and lecture fees. Achim Rody reports a relationship with Roche that includes: speaking and lecture fees. Achim Rody reports a relationship with Pfizer that includes: speaking and lecture fees and travel reimbursement. Achim Rody reports a relationship with Novartis that includes: speaking and lecture fees. Achim Rody reports a relationship with Celgene SL that includes: speaking and lecture fees. Achim Rody reports a relationship with ExactSciences that includes: speaking and lecture fees. Achim Rody reports a relationship with Pierre Fabre SA that includes: speaking and lecture fees. Achim Rody reports a relationship with Eli Lilly and Company that includes: speaking and lecture fees. Achim Rody reports a relationship with Seagen that includes: speaking and lecture fees. Achim Rody reports a relationship with Astra Zeneca that includes: speaking and lecture fees. Achim Rody reports a relationship with Eisai that includes: speaking and lecture fees. Achim Rody reports a relationship with MSD that includes: speaking and lecture fees. Achim Rody reports a relationship with Hexal that includes: speaking and lecture fees. Achim Rody reports a relationship with Amgen that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Roche that includes: speaking and lecture fees and travel reimbursement. Maggie Banys-Paluchowski reports a relationship with Novartis that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Pfizer that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with pfm that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Eli Lilly and Company that includes: speaking and lecture fees and travel reimbursement. Maggie Banys-Paluchowski reports a relationship with Onkowissen that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Seagen that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Astra Zeneca that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Amgen that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Samsung that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Canon that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with MSD that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with GSK that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Daichii Sankyo that includes: speaking and lecture fees and travel reimbursement. Maggie Banys-Paluchowski reports a relationship with Gilead that includes: funding grants and speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Sirius Medical that includes: funding grants and speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Syantra that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with resitu that includes: speaking and lecture fees. Maggie Banys-Paluchowski reports a relationship with Pierre Fabre that includes: speaking and lecture fees and travel reimbursement. Maggie Banys-Paluchowski reports a relationship with ExactSciences that includes: funding grants, speaking and lecture fees, and travel reimbursement. Maggie Banys-Paluchowski reports a relationship with Dampf Stiftung that includes: funding grants. Maggie Banys-Paluchowski reports a relationship with AWOgyn that includes: funding grants. Maggie Banys-Paluchowski reports a relationship with AGO-B that includes: funding grants. Claudia von Schilling reports a relationship with Claudia von Schilling Breast Cancer Research Foundation that includes: funding grants. Maggie Banys-Paluchowski reports a relationship with Ehmann Stiftung that includes: funding grants. Maggie Banys-Paluchowski reports a relationship with EndoMag that includes: funding grants. Maggie Banys-Paluchowski reports a relationship with Mammotome that includes: funding grants. Maggie Banys-Paluchowski reports a relationship with MeritMedical that includes: funding grants. Maggie Banys-Paluchowski reports a relationship with Hologic that includes: funding grants. Maggie Banys-Paluchowski is Associate Editor of Archives of Gynecology and Obstetrics and the European Journal of Surgical Oncology. Melissa Neubacher reports a relationship with Mammotome that includes: travelling grant. Niklas Amann reports a relationship with Gilead that includes: speaking and lecture fees. Niklas Amann reports a relationship with Georg Thieme Verlag KG that includes: board membership and non-financial support. Niklas Amann reports a relationship with Astra Zeneca that includes: travel reimbursement. Niklas Amann reports a relationship with Novartis that includes: travel reimbursement. Niklas Amann reports a relationship with Pfizer that includes: travel reimbursement. Franziska Fick reports a relationship with Novartis that includes: speaking and lecture fees and travel reimbursement. Franziska Fick reports a relationship with Astra Zeneca that includes: travel reimbursement. Irene Esposito reports a relationship with Amgen that includes: speaking and lecture fees. Irene Esposito reports a relationship with Falk that includes: speaking and lecture fees. Irene Esposito reports a relationship with BMS that includes: speaking and lecture fees. Maximilian Seidl reports a relationship with Recordati Rare Diseases that includes: speaking and lecture fees and travel reimbursement. Kerstin Muras reports a relationship with Pfizer that includes: speaking and lecture fees and travel reimbursement. Kerstin Muras reports a relationship with Astra Zeneca that includes speaking and lecture fees and travel reimbursement. Kerstin Muras reports relationships with Celgene that includes speaking and lecture fees. Kerstin Muras reports a relationship with Dampf Stiftung that includes: funding grants. Kerstin Muras reports relationships with BioNTech that includes travel reimbursement.Fabian Kohls reports a relationship with Pfizer that includes: speaking and lecture fees. Fabian Kohls reports a relationship with Lilly that includes: speaking and lecture fees. Fabian Kohls reports a relationship with AstraZeneca that includes: speaking and lecture fees.Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was carried out in accordance with the guidelines of the Declaration of Helsinki and approved by the Ethical Committee of the University of L\u00fcbeck (file number: 2024\u2009\u2212\u2009440; date of approval 23.08.2024) and University of D\u00fcsseldorf (file number: 2024\u20132795; date of approval: 22.04.2024).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"148"}}